Stock Yards Bank & Trust Co. grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 36,859 shares of the company’s stock after buying an additional 1,203 shares during the period. Stock Yards Bank & Trust Co.’s holdings in Eli Lilly and were worth $3,153,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of the business. Accredited Investors Inc. increased its position in Eli Lilly and by 0.4% during the 2nd quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock worth $268,000 after buying an additional 14 shares during the period. Northwest Quadrant Wealth Management LLC increased its position in Eli Lilly and by 0.5% during the 1st quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock worth $290,000 after buying an additional 19 shares during the period. Oakworth Capital Inc. increased its position in Eli Lilly and by 0.3% during the 2nd quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock worth $552,000 after buying an additional 20 shares during the period. Sfmg LLC increased its position in Eli Lilly and by 0.5% during the 2nd quarter. Sfmg LLC now owns 4,258 shares of the company’s stock worth $350,000 after buying an additional 20 shares during the period. Finally, Jackson Grant Investment Advisers Inc. increased its position in Eli Lilly and by 0.7% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,647 shares of the company’s stock worth $300,000 after buying an additional 24 shares during the period. Hedge funds and other institutional investors own 76.43% of the company’s stock.
In other news, SVP Alfonso G. Zulueta sold 2,003 shares of Eli Lilly and stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the sale, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Lilly Endowment Inc sold 205,000 shares of Eli Lilly and stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $86.81, for a total value of $17,796,050.00. The disclosure for this sale can be found here. Insiders have sold 592,003 shares of company stock worth $50,246,641 over the last three months. Insiders own 0.20% of the company’s stock.
LLY has been the topic of a number of recent analyst reports. BMO Capital Markets restated a “sell” rating and issued a $71.00 price target on shares of Eli Lilly and in a research report on Thursday, September 28th. Morgan Stanley set a $86.00 price target on Eli Lilly and and gave the stock a “hold” rating in a research report on Friday, October 6th. Piper Jaffray Companies restated a “buy” rating and issued a $105.00 price target on shares of Eli Lilly and in a research report on Friday, October 13th. Jefferies Group restated a “buy” rating and issued a $89.00 price target (down previously from $94.00) on shares of Eli Lilly and in a research report on Thursday, August 24th. Finally, Goldman Sachs Group restated a “buy” rating and issued a $95.00 price target (up previously from $92.00) on shares of Eli Lilly and in a research report on Thursday, October 5th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $90.25.
Shares of Eli Lilly and Company (LLY) traded up $0.26 during mid-day trading on Tuesday, hitting $85.58. The stock had a trading volume of 4,228,200 shares, compared to its average volume of 3,671,792. Eli Lilly and Company has a 12-month low of $66.39 and a 12-month high of $89.09. The firm has a market capitalization of $93,945.43, a price-to-earnings ratio of 20.86, a price-to-earnings-growth ratio of 1.87 and a beta of 0.35. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, beating the Zacks’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. During the same period last year, the firm posted $0.88 earnings per share. The business’s revenue for the quarter was up 9.0% on a year-over-year basis. analysts forecast that Eli Lilly and Company will post 4.21 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.43%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s payout ratio is 98.58%.
COPYRIGHT VIOLATION NOTICE: “Stock Yards Bank & Trust Co. Purchases 1,203 Shares of Eli Lilly and Company (LLY)” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2017/12/05/stock-yards-bank-trust-co-purchases-1203-shares-of-eli-lilly-and-company-lly.html.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.